Alzamend Neuro (ALZN) Price Target Lowered to $45.00; Buy Rating Maintained

Ascendiant Capital's Edward Woo maintains a "Buy" rating for Alzamend Neuro (ALZN) but lowers the price target from $180 to $45, a 75% reduction. This adjustment reflects a more conservative outlook while still retaining confidence in the stock's potential. Alzamend Neuro is an early clinical-stage biopharmaceutical company focused on developing novel products for neurodegenerative diseases and psychiatric disorders.

Top Wall Street analysts have recently updated their price targets and ratings for a variety of stocks, with some significant changes impacting the biopharmaceutical sector. Ascendiant Capital, in particular, has made a notable adjustment to its price target for Alzamend Neuro, Inc. (ALZN), a company focused on developing novel products for neurodegenerative diseases and psychiatric disorders.

Ascendiant Capital analyst Edward Woo has maintained a "Buy" rating for ALZN but has lowered the price target from $180 to $45, a 75% reduction. This adjustment reflects a more conservative outlook while still retaining confidence in the stock's potential. The change in price target comes amidst broader market volatility and uncertainty, suggesting that analysts are being cautious in their assessments.

Alzamend Neuro shares closed at $2.26 on Wednesday, July 2, 2025, according to the latest available data. The company's early clinical-stage biopharmaceutical pipeline includes innovative treatments for neurodegenerative diseases and psychiatric disorders, which hold significant promise for the future of healthcare.

Other notable changes in analyst ratings and price targets include Needham raising the price target for I-Mab (NASDAQ:IMAB) from $5 to $6, and Piper Sandler cutting the price target for Civitas Resources, Inc. (NYSE:CIVI) from $54 to $52. These adjustments underscore the dynamic nature of the market and the importance of staying informed about the latest analyst views.

For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page [1].

References:
[1] https://www.inkl.com/news/hewlett-packard-enterprise-to-rally-around-33-here-are-10-top-analyst-forecasts-for-thursday